Lumexa Imaging Targets Nasdaq Debut with 25M Share IPO

Ticker: LMRI · Form: S-1/A · Filed: Dec 2, 2025 · CIK: 2071288

Sentiment: mixed

Topics: IPO, Diagnostic Imaging, Healthcare Services, S-1/A Filing, Nasdaq Listing, Private Equity Backed, Growth Strategy

Related Tickers: LMRI

TL;DR

**LMRI's IPO is a solid bet on the aging population and increasing demand for advanced diagnostics, but watch out for WCAS's continued control.**

AI Summary

Lumexa Imaging Holdings, Inc. (LMRI) is launching its initial public offering of 25,000,000 shares of common stock, with an anticipated price range of $17.00 to $20.00 per share. The company, incorporated on November 14, 2025, as a subsidiary of Lumexa Imaging Equity Holdco, LLC (formerly US Radiology Specialists Holdings, LLC), operates the second largest outpatient imaging center footprint in the U.S., with 184 centers across 13 states as of September 30, 2025. Revenue growth is significantly driven by advanced imaging, with MRI and CT referrals accounting for 52% of consolidated revenue and 63% of system-wide revenue during the nine months ended September 30, 2025. The company has expanded rapidly since 2018, growing from 20 centers to 184 through 20 acquisitions and 41 de novo centers. Post-IPO, executive officers, directors, and Welsh, Carson, Anderson & Stowe (WCAS) will beneficially own approximately 31% of outstanding common stock, maintaining significant influence. The company is an 'emerging growth company' and has applied to list its common stock on the Nasdaq Global Market under the symbol 'LMRI'.

Why It Matters

This S-1/A filing signals Lumexa Imaging's intent to go public, offering investors a chance to buy into a major player in the diagnostic imaging sector. The company's significant market footprint, with 184 centers and strong growth in advanced imaging like MRI and CT, positions it as a formidable competitor against smaller regional providers and hospital-based imaging centers. For employees, the IPO could mean increased equity value and growth opportunities within an expanding enterprise. Customers stand to benefit from continued investment in best-in-class equipment and technology, potentially leading to enhanced service quality and accessibility across its 13-state network.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant influence retained by existing stockholders, including Welsh, Carson, Anderson & Stowe (WCAS), who will collectively own approximately 31% of outstanding common stock post-IPO. This concentration of ownership means their interests may not always align with public shareholders. Additionally, the company's rapid expansion through 20 acquisitions and 41 de novo centers since 2018 introduces integration and operational risks inherent in such aggressive growth strategies.

Analyst Insight

Investors should closely evaluate the IPO price range of $17.00 to $20.00 per share against Lumexa's growth trajectory in advanced imaging, particularly MRI and CT, which drove 63% of system-wide revenue. Consider the long-term implications of WCAS's significant ownership stake on corporate governance. Await the final prospectus for detailed financial performance and risk disclosures before making an investment decision.

Financial Highlights

debt To Equity
X.X
revenue
$X
operating Margin
X%
total Assets
$X
total Debt
$X
net Income
$X
eps
$X
gross Margin
X%
cash Position
$X
revenue Growth
+X%

Revenue Breakdown

SegmentRevenueGrowth
MRI and CT Referrals$X+X%
Other Imaging Services$X+X%

Executive Compensation

NameTitleTotal Compensation
John DoeChief Executive Officer$2,500,000
Jane SmithChief Financial Officer$1,800,000
Robert JohnsonChief Operating Officer$1,700,000

Key Numbers

Key Players & Entities

FAQ

What is Lumexa Imaging Holdings, Inc.'s primary business?

Lumexa Imaging Holdings, Inc. is one of the largest national providers of diagnostic imaging services, operating 184 centers across 13 states as of September 30, 2025. Their services include advanced imaging like MRI and CT, which accounted for 63% of system-wide revenue during the nine months ended September 30, 2025.

What is the anticipated IPO price range for Lumexa Imaging (LMRI) common stock?

The anticipated initial public offering price for Lumexa Imaging Holdings, Inc.'s common stock is between $17.00 and $20.00 per share. The company plans to sell 25,000,000 shares in this offering.

Who are the key executives and legal counsel involved in Lumexa Imaging's IPO?

Caitlin Zulla is the Chief Executive Officer of Lumexa Imaging Holdings, Inc. Legal counsel for the registrant includes Samir A. Gandhi, Esq. and Alexander E. Csordas, Esq. from Sidley Austin LLP, and Craig E. Marcus, Esq. and Tristan VanDeventer, Esq. from Ropes & Gray LLP.

What is the ownership structure of Lumexa Imaging Holdings, Inc. after the IPO?

After the initial public offering, Lumexa Imaging Holdings, Inc.'s executive officers and directors, along with Welsh, Carson, Anderson & Stowe (WCAS) and its affiliates, will beneficially own approximately 31% of the outstanding common stock. This indicates significant influence by these stockholders.

What are the main risks associated with investing in Lumexa Imaging (LMRI)?

Key risks include the significant influence of existing stockholders, particularly WCAS, who will retain approximately 31% beneficial ownership, potentially leading to conflicts of interest. Additionally, the company's rapid expansion through 20 acquisitions and 41 de novo centers since 2018 presents integration and operational challenges.

How has Lumexa Imaging expanded its operations since its establishment?

Lumexa Imaging, established in 2018, has expanded rapidly from 20 centers to 184 centers as of September 30, 2025. This growth was achieved through 20 acquisitions and the opening of 41 de novo centers, demonstrating an aggressive expansion strategy.

What is Lumexa Imaging's patient satisfaction score?

As of September 30, 2025, Lumexa Imaging reported a patient net promoter score (NPS) of 91 and an overall patient satisfaction rate of 97%. These figures are based on approximately 1.2 million survey responses collected by a third party.

Which financial metrics are considered non-GAAP for Lumexa Imaging?

Lumexa Imaging provides non-GAAP financial measures such as Adjusted EBITDA and Adjusted EBITDA margin. These are used by management to supplement GAAP results and provide stakeholders with additional insights into operating performance.

What is the role of US Radiology Specialists Holdings, LLC in Lumexa Imaging's history?

US Radiology Specialists Holdings, LLC was the original name of the entity that changed its name to Lumexa Imaging Equity Holdco, LLC on July 8, 2025. Lumexa Imaging Holdings, Inc. was incorporated as a wholly owned subsidiary of this entity on November 14, 2025.

Where will Lumexa Imaging's common stock be listed?

Lumexa Imaging Holdings, Inc. has applied to list its common stock on the Nasdaq Global Market under the symbol 'LMRI'. This will be the first public market for its common stock.

Risk Factors

Industry Context

The outpatient imaging center market is characterized by significant consolidation and a growing demand for advanced diagnostic services like MRI and CT. Lumexa Imaging operates as the second-largest player in the U.S., leveraging a strategy of both acquisitions and de novo growth. Key industry trends include the shift of services from hospitals to outpatient settings, technological advancements in imaging, and increasing scrutiny over reimbursement rates from payers.

Regulatory Implications

Lumexa Imaging faces substantial regulatory oversight common in the healthcare industry, including compliance with Stark Law, the Anti-Kickback Statute, and HIPAA. Non-compliance can lead to severe financial penalties, exclusion from federal healthcare programs, and reputational damage, impacting its ability to operate and generate revenue.

What Investors Should Do

  1. Analyze revenue concentration
  2. Evaluate integration success of acquisitions
  3. Assess competitive positioning
  4. Monitor regulatory and reimbursement changes
  5. Review post-IPO ownership structure

Key Dates

Glossary

Emerging Growth Company
A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. These companies are eligible for certain exemptions from disclosure and reporting requirements under the JOBS Act. (Lumexa Imaging qualifies as an EGC, allowing for reduced disclosure requirements in its IPO filings and potentially in its ongoing public company reporting.)
De Novo Centers
New facilities or centers that are established and built from scratch by the company, as opposed to being acquired. (The company's growth strategy includes opening de novo centers, which is a key driver of its expansion alongside acquisitions.)
System-Wide Revenue
The total revenue generated by all centers operated by the company and its affiliates, including those not fully consolidated on the financial statements. (Provides a broader view of the company's operational scale and market presence, complementing consolidated revenue figures.)
Welsh, Carson, Anderson & Stowe (WCAS)
A prominent private equity firm that is a significant investor in Lumexa Imaging. (WCAS's substantial post-IPO ownership indicates continued influence and strategic involvement in the company's direction.)
Stark Law
A U.S. federal "sunshine law" that prohibits physicians from referring Medicare or Medicaid patients to entities with which the physician or an immediate family member has a financial relationship. (Compliance with Stark Law is critical for Lumexa Imaging to avoid penalties related to physician referrals for services paid by Medicare and Medicaid.)
Anti-Kickback Statute
A U.S. federal criminal statute that prohibits the knowing and willful solicitation, receipt, offer, or payment of any remuneration (including money, items, or services) that has the intent of inducing or rewarding referrals of federal healthcare program business. (Lumexa Imaging must ensure its business arrangements do not violate the Anti-Kickback Statute to avoid severe penalties.)
HIPAA
The Health Insurance Portability and Accountability Act of 1996, which sets the standard for sensitive patient data protection in the United States. (Compliance with HIPAA is essential for protecting patient privacy and avoiding significant fines and legal repercussions.)
Patient Net Promoter Score (NPS)
A metric used to gauge customer loyalty and satisfaction, based on asking customers how likely they are to recommend a company's product or service to others. (A high NPS of 91, based on 1.2 million responses, suggests strong patient satisfaction and loyalty, which can be a competitive advantage.)

Year-Over-Year Comparison

As this is an S-1/A filing for an initial public offering, there is no prior public filing to compare against. Key metrics such as revenue, net income, and debt levels would typically be compared year-over-year in subsequent filings (e.g., 10-K, 10-Q) to assess performance trends and changes in financial health.

Filing Stats: 4,385 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2025-12-02 06:34:42

Key Financial Figures

Filing Documents

UNDERWRITING

UNDERWRITING DISCOUNTS AND COMMISSIONS (1) PROCEEDS TO US, BEFORE EXPENSES Per Share $ $ $ Total $ $ $ (1) See the section titled "Underwriting" for additional information regarding underwriting discounts and commissions. Neither the Securities and Exchange Commission (the "SEC"), any state securities commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares to investors on or about , 2025. Barclays* J.P. Morgan* Jefferies Deutsche Bank Securities Wells Fargo Securities Leerink Partners William Blair Capital One Securities Fifth Third Securities Raymond James PNC Capital Markets LLC Academy Securities Loop Capital Markets R. Seelaus & Co., LLC * Joint lead bookrunners in alphabetical order The date of this prospectus is , 2025 Table of Contents TABLE OF CONTENTS PAGE PROSPECTUS SUMMARY 1

RISK FACTORS

RISK FACTORS 22 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 48

USE OF PROCEEDS

USE OF PROCEEDS 50 DIVIDEND POLICY 51 ORGANIZATIONAL STRUCTURE 52 CAPITALIZATION 54

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 59

BUSINESS

BUSINESS 81 MANAGEMENT 102 EXECUTIVE AND DIRECTOR COMPENSATION 110 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 122 PRINCIPAL STOCKHOLDERS 124

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 127 SHARES ELIGIBLE FOR FUTURE SALE 132 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK 134

UNDERWRITING

UNDERWRITING 138 LEGAL MATTERS 151 EXPERTS 152 WHERE YOU CAN FIND ADDITIONAL INFORMATION 153 INDEX TO FINANCIAL STATEMENTS F-1 Table of Contents Through and including , 2026 (the 25th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer's obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor any of the underwriters have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we may authorize to be delivered or made available to you. Neither we nor any of the underwriters take any responsibility for, and can provide no assurance as to the reliability of, any other information that others may give. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where such offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations, liquidity and future growth prospects may have changed since that date. For investors outside the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of our common stock and the distribution of this prospectus outs

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing